Dec. 1 at 6:37 PM
$MSDD The colorectal cancer screening and diagnostics market is heading into the tens of billions of dollars by 2030 and beyond, and Mainz Biomed sits right in the center of that trend while still being valued by the market like a tiny startup โ the gap between potential and current price is huge